NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $592.84 +5.34 (+0.91%) Closing price 10/26/2026 04:00 PM EasternExtended Trading$554.51 -38.33 (-6.47%) As of 06:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About United Therapeutics Stock (NASDAQ:UTHR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get United Therapeutics alerts:Sign Up Key Stats Today's Range$584.50▼$593.5050-Day Range$472.21▼$592.8452-Week Range$409.07▼$609.35Volume559,766 shsAverage Volume934,279 shsMarket Capitalization$25.43 billionP/E Ratio21.21Dividend YieldN/APrice Target$666.50Consensus RatingModerate Buy Company Overview United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH. The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer. United Therapeutics sells its products through healthcare providers and specialty pharmacies, primarily in the United States, with selected products available in international markets subject to local regulatory approvals. Founded in 1996 by Martine Rothblatt, United Therapeutics has expanded beyond pharmaceutical development into organ manufacturing and transplantation research. Through subsidiaries and affiliated operations, including Lung Biotechnology and Revivicor, the company is working on technologies intended to increase the availability of transplantable lungs and other organs, including regenerative medicine and genetically engineered animal organs. Rothblatt serves as the company’s chairperson and chief executive officer.AI Generated. May Contain Errors. Read More United Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreUTHR MarketRank™: 4.520165996625 of 5 starsUnited Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 74th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 12 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialUnited Therapeutics has a consensus price target of $666.50, representing about 12.4% upside from its current price of $592.84.Amount of Analyst CoverageUnited Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.46% Earnings GrowthEarnings for United Therapeutics are expected to grow by 16.46% in the coming year, from $26.07 to $30.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 21.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.11.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 21.21, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.91.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 4.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.27% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 2.57, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently decreased by 31.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.62 News SentimentUnited Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 28 news articles for United Therapeutics this week, compared to 11 articles on an average week.Search Interest12 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $213,874,881.00 in company stock.Percentage Held by Insiders8.60% of the stock of United Therapeutics is held by insiders.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UTHR Stock News HeadlinesUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock3 hours ago | insidertrades.comUnited Therapeutics (NASDAQ: UTHR) CEO sells shares in prearranged plan4 hours ago | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 27 at 1:00 AM | Porter & Company (Ad)United Therapeutics (NASDAQ:UTHR) to Buy Back $2.00 billion in StockOctober 24 at 1:13 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Elevance Health (ELV) and Abbott Laboratories (ABT)October 23, 2026 | theglobeandmail.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,161,540.00 in StockOctober 23, 2026 | americanbankingnews.comUnited Therapeutics' Tyvaso Outlook Faces Near-Term Pressure After Liquidia Settlement, RBC SaysOctober 22, 2026 | finance.yahoo.comInsider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Company StockOctober 17, 2026 | insidertrades.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $487.25 at the start of the year. Since then, UTHR shares have increased by 21.7% and is now trading at $592.84. How were United Therapeutics' earnings last quarter? United Therapeutics Corporation (NASDAQ:UTHR) announced its earnings results on Wednesday, August, 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics's revenue was down 1.9% compared to the same quarter last year. Read the conference call transcript. Is United Therapeutics buying back stock? United Therapeutics' Board of Directors approved a stock buyback program on Thursday, October 22nd 2026, which allows the company to buy back $2 billion in outstanding shares, according to EventVestor. This means that the company could reacquire up to 8.3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued. Who are United Therapeutics' major shareholders? United Therapeutics' top institutional shareholders include Robeco Institutional Asset Management B.V. (0.34%), Assenagon Asset Management S.A. (0.16%), Atwood & Palmer Inc. (0.14%) and Apollon Wealth Management LLC (0.05%). Insiders that own company stock include Martine A Rothblatt, Paul A Mahon, Richard Giltner, James Edgemond, Ray Kurzweil, Tommy G Thompson, Nilda Mesa, Judy D Olian, Christopher Causey, Raymond Dwek, Christopher Patusky, Jan Malcolm, Michael Benkowitz and Louis W Sullivan. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Bristol Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/05/2026Today10/27/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, UTHR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,400Year Founded1996Price Target and Rating Average Price Target for United Therapeutics$666.50 High Price Target$850.00 Low Price Target$368.00 Potential Upside/Downside+12.4%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$27.95 Trailing P/E Ratio21.21 Forward P/E Ratio22.74 P/E Growth4.26Net Income$1.33 billion Net Margins41.56% Pretax Margin49.87% Return on Equity20.18% Return on Assets17.98% Debt Debt-to-Equity RatioN/A Current Ratio5.73 Quick Ratio5.41 Sales & Book Value Annual Sales$3.18 billion Price / Sales7.99 Cash Flow$33.29 per share Price / Cash Flow17.81 Book Value$164.81 per share Price / Book3.60Miscellaneous Outstanding Shares42,890,000Free Float39,202,000Market Cap$25.43 billion OptionableOptionable Beta0.49 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:UTHR) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
